Extended‐release methylphenidate vs placebo
Quality of life, self‐rated at post‐treatment · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
- Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2022 · Cochrane Headline outcomes onlyno estimate extracted6 studies · 1888 participantsVery low